Thermo Fisher Scientific Wins Three R&D 100 Awards Category: Corporate
Thermo Fisher Scientific Inc. has announced that three of its analytical instruments were included on the R&D Magazine list of the year’s top 100 technology innovations. Known as the “Oscars of Innovation,” the R&D 100 recognises the best new products across industry, academia and government-sponsored research.
“Innovation is a key component of our growth strategy and critical to fulfilling our mission, which is to enable our customers to make the world healthier, cleaner and safer,” said Marc N. Casper, president and chief executive officer of Thermo Fisher Scientific. “The R&D 100 awards recognise our commitment to technology development and our focus on giving customers the tools they need to achieve their own goals for innovation and productivity.”
The award-winning products are
• Thermo Scientific Delta Ray, an isotope ratio infrared spectrometer that enables scientists to monitor volcanos, greenhouse gases, plant ecology, and carbon capture and storage, among other applications for CO2 analysis. The Delta Ray spectrometer gives scientists real-time results at the sample source, eliminating bottlenecks created when transporting samples from the field to the lab.
• Thermo Scientific RIIDEye X, a handheld radiation isotope identifier designed to detect gamma and neutron radiation sources and provide information on location, type and quantity. The RIIDEye X delivers fast, accurate readings in harsh operating conditions, making it ideal for military personnel, first responders and field-based researchers.
• Thermo Scientific Dionex ERS 500, the first electrolytically regenerated, high-capacity membrane suppressor that eliminates the need for chemical reagents during ion chromatography analysis. Designed for use in environmental, food and beverage, and pharmaceutical markets, the ERS 500 suppressor is more pressure tolerant than previous technologies, a feature critical to long-term reliability.
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance